176 related articles for article (PubMed ID: 37010741)
1. Multi-regulator of EZH2-PPARs Therapeutic Targets: A Hallmark for Prospective Restoration of Pancreatic Insulin Production and Cancer Dysregulation.
Olowosoke CB; Gbemisola O; Alaba AA; Adepoju OH; Okorie B; Odjegba PI; Ogunsanmi AO; Oke GA; Akinlolu O; Olubena TL; Bello RO; Adegboyega BB
Appl Biochem Biotechnol; 2023 Dec; 195(12):7520-7552. PubMed ID: 37010741
[TBL] [Abstract][Full Text] [Related]
2. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
3. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
4. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M
Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
Misawa K; Yamaotsu N; Hirono S
J Comput Aided Mol Des; 2021 May; 35(5):601-611. PubMed ID: 33635506
[TBL] [Abstract][Full Text] [Related]
6. Design, sythesis and evaluation of a series of 3- or 4-alkoxy substituted phenoxy derivatives as PPARs agonists.
Zhang J; Wang XJ; Liu X; Huan Y; Yang MM; Shen ZF; Jia WQ; Jing Z; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Mar; 8(13):20766-20783. PubMed ID: 28186999
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of human EZH2 can influence a regenerative β-like cell capacity with in vitro insulin release in pancreatic ductal cells.
Naina Marikar S; Al-Hasani K; Khurana I; Kaipananickal H; Okabe J; Maxwell S; El-Osta A
Clin Epigenetics; 2023 Jun; 15(1):101. PubMed ID: 37309004
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
9. Bezafibrate Improves Insulin Sensitivity and Metabolic Flexibility in STZ-Induced Diabetic Mice.
Franko A; Huypens P; Neschen S; Irmler M; Rozman J; Rathkolb B; Neff F; Prehn C; Dubois G; Baumann M; Massinger R; Gradinger D; Przemeck GK; Repp B; Aichler M; Feuchtinger A; Schommers P; Stöhr O; Sanchez-Lasheras C; Adamski J; Peter A; Prokisch H; Beckers J; Walch AK; Fuchs H; Wolf E; Schubert M; Wiesner RJ; Hrabě de Angelis M
Diabetes; 2016 Sep; 65(9):2540-52. PubMed ID: 27284107
[TBL] [Abstract][Full Text] [Related]
10. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY; Zhang J; Zeng FY; Zhu YZ
Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
[TBL] [Abstract][Full Text] [Related]
11. [Polymorphisms of PPARs and metabolic disorders].
Araki E; Igata M; Motoshima H; Tsuruzoe K
Nihon Rinsho; 2005 Apr; 63(4):617-22. PubMed ID: 15828229
[TBL] [Abstract][Full Text] [Related]
12. Integrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing.
Li Y; Luo M; Shi X; Lu Z; Sun S; Huang J; Chen Z; He J
Oncotarget; 2016 Dec; 7(49):81715-81726. PubMed ID: 27835578
[TBL] [Abstract][Full Text] [Related]
13. Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer.
Hu J; Zheng Z; Lei J; Cao Y; Li Q; Zheng Z; Chen C
PPAR Res; 2021; 2021():5589342. PubMed ID: 34335707
[TBL] [Abstract][Full Text] [Related]
14. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
15. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
16. Identifying natural compounds as multi-target-directed ligands against Alzheimer's disease: an in silico approach.
Ambure P; Bhat J; Puzyn T; Roy K
J Biomol Struct Dyn; 2019 Mar; 37(5):1282-1306. PubMed ID: 29578387
[TBL] [Abstract][Full Text] [Related]
17. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
[TBL] [Abstract][Full Text] [Related]
18. Systematic Evaluation of the Mechanisms of Mulberry Leaf (Morus alba Linne) Acting on Diabetes Based on Network Pharmacology and Molecular Docking.
Wu Q; Hu Y
Comb Chem High Throughput Screen; 2021; 24(5):668-682. PubMed ID: 32928080
[TBL] [Abstract][Full Text] [Related]
19. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
20. Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.
Morschhauser F; Salles G; Batlevi CL; Tilly H; Chaidos A; Phillips T; Burke J; Melnick A
Blood Rev; 2022 Nov; 56():100988. PubMed ID: 35851487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
